TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6560416
Drug: Technique 2
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique 2 for administering subcutaneous low-dose heparin
Study: 6560416
Drug: Technique 3
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique 3 for administering subcutaneous low-dose heparin
Study: 18497320
Drug: Continue anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue anticoagulants for 9 additional months (RVT group)
Study: 18497320
Drug: Stop anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop anticoagulants (RVT group)
Study: 12574190
Drug: 60‐65 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐65 mg iodide daily for 60 days (group A)
Study: 12574190
Drug: 60‐65 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐65 mg iodide daily for 60 days (group B)
Study: 12574190
Drug: 60‐65 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐65 mg iodide daily for 60 days (group C)
Study: 12574190
Drug: 60‐65 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐65 mg iodide daily for 60 days (all groups)
Study: 12574190
Drug: 60‐65 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐65 mg iodide daily for 60 days (group D)
Study: 10417466
Drug: Nefopam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (0.15 mg.kg‐1)
Study: 8745846
Drug: Peak flow
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak flow measurements (weekly)
Study: 1906004
Drug: Ro 19-6327
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 19-6327 (10 to 50 mg oral pre-dose)
Study: 1906004
Drug: L‐deprenyl (tracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐deprenyl (tracer alone)
Study: 24569690
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra) at a dose of 100 mg subcutaneously once a day for 5 days
Study: 24569690
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra)
Study: 20329654
Drug: LOS/HCTZ (losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS/HCTZ (losartan 50 mg/day + hydrochlorothiazide 12.5 mg/day)
Study: 20329654
Drug: TEL/HCTZ (telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEL/HCTZ (telmisartan 40 mg/day + hydrochlorothiazide 12.5 mg/day)
Study: 20329654
Drug: CND/HCTZ (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CND/HCTZ (candesartan 8 mg/day + hydrochlorothiazide 12.5 mg/day)
Study: 11707842
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy (cyclophosphamide/doxorubicin/vincristine/prednisone)
Study: 11707842
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factors added to CHOP chemotherapy
Study: 11707842
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy followed by autologous stem cell transplantation
Study: 11707842
Drug: New lymphoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: New lymphoma treatments with improved toxicity profiles
Study: 7506168
Drug: nimesulide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (300 mg/day)
Study: 7506168
Drug: naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (750 mg/day)
Study: 26457580
Drug: Tesamorelin 2
Normalized name: tesamorelin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesamorelin 2 mg subcutaneously daily for 6 months
Study: 11744430
Drug: 3.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/day oral ganciclovir
Study: 11744430
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day oral ganciclovir
Study: 11744430
Drug: 6.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 g/day oral ganciclovir
Study: 11744430
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day IV ganciclovir
Study: 2479303
Drug: terfenadine, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine, 240 mg
Study: 2479303
Drug: terfenadine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine, 120 mg
Study: 31290344
Drug: ADT +
Normalized name: Antidepressant+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT + brexpiprazole 1-3 mg/day
Study: 26255512
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Zusanli (ST 36) combined with oral administration of Gexia Zhuyu decoction
Study: 26255512
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment combined with oral administration of Gexia Zhuyu decoction
Study: 21624752
Drug: Daily montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily montelukast 4 mg
Study: 21624752
Drug: Intermittent montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent montelukast 4 mg
Study: 19537367
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream applied to one side of the scalp and/or face for 12 weeks
Study: 19537367
Drug: Ultrabase cream
Normalized name: Ultrasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrabase cream (placebo) applied to the other side for 12 weeks
Study: 16423001
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL)
Study: 16423001
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple)
Study: 16423001
Drug: Lansoprazole, amoxicillin
Normalized name: lansoprazole, amoxicillin and levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, amoxicillin plus levofloxacin (LAL)
Study: 15229013
Drug: Concentrated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated intravenous oxytocin plus low-dose vaginal PGE(2) 10 mg every 6 hours 4x
Study: 8431124
Drug: Two 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 5% povidone‐iodine enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 1)
Study: 8431124
Drug: Single injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) and two 5% povidone‐iodine enemas (Group 2)
Study: 8431124
Drug: Saline enemas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 3)
Study: 8431124
Drug: Single injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) (Group 2)
Study: 2887112
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms, four times daily for four weeks)
Study: 23610100
Drug: Colestilan 9
Normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan 9 g/day
Study: 23610100
Drug: Colestilan 12/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan 12/15 g/day (pooled)
Study: 23610100
Drug: Colestilan 3
Normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan 3 g/day
Study: 23610100
Drug: Colestilan 6
Normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan 6 g/day
Study: 23610100
Drug: Colestilan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan (various doses)
Study: 19128767
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific analgesic intervention (control group)
Study: 12723458
Drug: Immediate-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation of Fampridine (10 mg) in patients with spinal cord injury (n = 11)
Study: 12723458
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (n = 6) receiving oral doses of 10, 15, 20, and 25 mg of Fampridine
Study: 9043560
Drug: Tetracaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 4% cream (30-minute application)
Study: 9043560
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (60-minute application)
Study: 8438775
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg/d)
Study: 28495562
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor with no predicted-active NRTIs
Study: 28495562
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor and raltegravir
Study: 23349733
Drug: L-carnitine (510
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (510 mg/day)
Study: 14698699
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (carbamazepine, phenytoin, or valproate)
Study: 3698521
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg daily + Nifedipine 30 mg daily
Study: 31489188
Drug: Lemna minor
Normalized name: LEMNA MINOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemna minor (20 g of protein)
Study: 31489188
Drug: Green peas
Normalized name: green english pea allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green peas (20 g of protein)
Study: 23669062
Drug: AM (Amlodipine)
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM (Amlodipine) 10 mg/day + OM (Olmesartan Medoxomil) 40 mg/day
Study: 23669062
Drug: AM (Amlodipine)
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM (Amlodipine) 10 mg/day
Study: 23669062
Drug: OM (Olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM (Olmesartan Medoxomil) 40 mg/day
Study: 21515838
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 or 100 mg daily) in the diet-alone group
Study: 21515838
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 or 100 mg daily) in the insulin group
Study: 21515838
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 or 100 mg daily) in the OHA group
Study: 21515838
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin in the insulin group
Study: 21515838
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin in the OHA group
Study: 21515838
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin in the diet-alone group
Study: 17038073
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care with access to a depression care manager and Problem Solving Treatment for 12 months
Study: 11558482
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Atorvastatin vs Simvastatin
Study: 8697067
Drug: Orlistat 50
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 50 mg three times a day
Study: 25562115
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) program, 6-week, six-lesson
Study: 23745303
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine hydrochloride 20 mL mixed with morphine 3 mg
Study: 20873998
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RF and topical steroid treatment
Study: 10791374
Drug: Treatment guided
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment guided by plasma N‐BNP concentration (BNP group)
Study: 8369005
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release diltiazem (180 mg)
Study: 8369005
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release diltiazem (240 mg)
Study: 8369005
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release diltiazem (300 mg)
Study: 8369005
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release diltiazem (360 mg)
Study: 8369005
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release diltiazem (60 mg, thrice a day)
Study: 31479032
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 3, 6.25, 12.5, or 25 mg weekly intramuscular injections
Study: 29096836
Drug: Weekly lipoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly lipoprotein apheresis by cascade plasma filtration (CPF) plus atorvastatin
Study: 21444866
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy and surgery (CS group; n = 113)
Study: 18649004
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (treatment group)
Study: 15112937
Drug: Promising medications
Normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promising medications
Study: 16350386
Drug: Low coronary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low coronary perfusion pressure at 50 mmHg for 90 seconds followed by high at 80 mmHg for 90 seconds (group L‐H)
Study: 16350386
Drug: High coronary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High coronary perfusion pressure at 80 mmHg for 90 seconds followed by low at 50 mmHg for 90 seconds (group H‐L)
Study: 12135589
Drug: Dexamethasone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (24 mg/day) for 4 days and atracurium (0.3-0.6 mg/kg/h) for 2.8 days (group C)
Study: 12135589
Drug: Dexamethasone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (24 mg/day) for 4 days (group B)
Study: 7631051
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and sulindac
Study: 7631051
Drug: Certain antihypertensive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Certain antihypertensive drugs (Ca2+ channel blockers, centrally acting alpha agonists, diuretics)
Study: 7631051
Drug: Thromboxane synthase
Normalized name: Thromboxane synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboxane synthase inhibitors and selective inhibitors of PGH synthase-2
Study: 2067035
Drug: Bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy with doxorubicin (60 mg/m2) and dacarbazine (750 mg/m2) intravenously on day 1
Study: 2067035
Drug: Infusional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional therapy with doxorubicin (60 mg/m2) and dacarbazine (750 mg/m2) delivered by continuous intravenous infusion for 96 hours on days 1-4
Study: 6223483
Drug: Previous oral
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous oral contraception use
Study: 21079521
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with paclitaxel and carboplatin (PCB)
Study: 20467615
Drug: 7‐mm‐long NanoTite
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐mm‐long NanoTite External Hex implants (Biomet 3i)
Study: 20467615
Drug: 10‐mm or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mm or longer implants placed in vertically augmented bone
Study: 20467615
Drug: Vertical bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical bone augmentation
Study: 20467615
Drug: 7‐mm short
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐mm short implants
Study: 17588704
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 over 30 min on Days 1 and 8 of a 21-day cycle (standard arm, N=33)
Study: 17588704
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 at a fixed dose rate of 10 mg/m2/min on Days 1 and 8 of a 21-day cycle (FDR arm, N=31)
Study: 15564706
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker (ARB) for 1 month
Study: 15564706
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker (ARB) for at least 6 months
Study: 15564706
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-hypertensive drugs other than ARB)
Study: 9388086
Drug: Control (Inpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Inpatient treatment)
Study: 7999471
Drug: Ideal combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ideal combination oral contraceptive
Study: 7999471
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist oophorectomy
Study: 7999471
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of estrogen metabolism
Study: 3297938
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pirenzepine tablets
Study: 27881559
Drug: CSL112 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (2 g apoA‐I per dose)
Study: 27881559
Drug: High-dose CSL112
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CSL112 (6 g apoA‐I per dose)
Study: 27881559
Drug: CSL112 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (2 g apoA‐I per dose) and High-dose CSL112 (6 g apoA‐I per dose)
Study: 22554598
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prasugrel
Study: 22554598
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prasugrel
Study: 20808309
Drug: ADI-PEG 20
Normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADI-PEG 20 at doses of 160 or 320 IU m(‐2)
Study: 16049208
Drug: Echinacea angustifolia
Normalized name: Echinacea Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea angustifolia extracts (three preparations: supercritical carbon dioxide, 60% ethanol, 20% ethanol)
Study: 12823436
Drug: 5% vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% vitamin C cream
Study: 1523350
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg pm
Study: 1523350
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg bi
Study: 6592034
Drug: Multiagent induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent induction and single-agent maintenance chemotherapy with randomization to an immunotherapy arm.
Study: 6592034
Drug: Elective surgical
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective surgical splenectomy performed for 42 patients at the completion of 3 months of induction therapy.
Study: 30279015
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg twice daily
Study: 24284444
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g · kg(‐1) · d(‐1) protein (2 × RDA)
Study: 24284444
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g · kg(‐1) · d(‐1) protein (3 × RDA)
Study: 24284444
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g · kg(‐1) · d(‐1) protein (RDA)
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid 2 mg/kg/h
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid 4 mg/kg/h
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid 6 mg/kg/h
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid 8 mg/kg/h
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid 10 mg/kg/h
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid 12 mg/kg/h
Study: 17389553
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid (all doses)
Study: 26222126
Drug: TAK-085 4
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-085 4 g/day
Study: 26222126
Drug: TAK-085 2
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-085 2 g/day